Registration Dossier

Administrative data

Link to relevant study record(s)

Description of key information

Key value for chemical safety assessment

Additional information

TDCP was well absorbed by the oral route of exposure and based on available studies, 100 % absorption will be assumed. In accordance with the default values given in the TGD, 100 % absorption via the inhalation route will also be assumed. An in vitro percutaneous absorption study using human skin membranes was conducted to determine the absorption following topical application of [14C]-TDCP. The skin membranes were exposed to TDCP for 8 hours, mimicking a normal working day. The mean total absorption was 15.4 %, 10.69 % and 6.0 %, for doses 0.003, 0.01 and 0.12 mg/cm2, respectively. A value of 15 % dermal absorption is taken forward to risk characterisation for exposure scenarios where there is potential exposure to “neat” TDCP and 30 % dermal absorption is assumed for scenarios 3, 4 and 5, where there is exposure due to handling of foam containing TDCP.

Distribution studies showed highest levels in the liver and kidney and lung following oral, dermal and i.v. administration. Tissue concentrations of either the parent compound or metabolites were always low due to rapid excretion. Rapid and extensive (essentially 100 %) oxidative metabolism, mainly to the metabolite bis (1,3-dichloro-2-propyl) phosphate (BDCP almost 70% of metabolites), occurred. Excretion was mainly via the urine (approx 50 %), but also occurred via faeces and expired air.

Elimination was rapid and so no accumulation in the body is expected.